Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Medis Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1052)
ARTG (149)
Cancellation or suspension (26)
Listed medicine compliance report (5)
Prescription medicine registration (2)

Date

2024 (866)
2023 (3)
2022 (29)
2021 (106)
2020 (31)
2019 (6)
2018 (6)
2017 (47)
2016 (5)
2015 (29)
2014 (29)
2013 (29)
2012 (23)
2011 (12)
2010 (3)
2009 (8)
2008 (1)
1993 (1)

Results for "[search-keyword]"

Search

Sponsor content

1234 result(s) found, displaying 571 to 580

ATORVASTATIN-GA atorvastatin (as calcium) 40 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CEFACLOR RAN cefaclor 375mg (as monohydrate) modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
LEZRA letrozole 2.5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
VALACICLOVIR ACTAVIS valaciclovir hydrochloride 1000mg tablet bottle Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
VACICLOR valaciclovir hydrochloride 1000mg tablet bottle Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
VALACICLOVIR ACTAVIS valaciclovir hydrochloride 1000mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
VALACICLOVIR ACTAVIS valaciclovir hydrochloride 250mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
IRINOTESIN 100mg/5mL irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
IRINOTESIN 40mg/2mL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
IRINOTESIN 500mg/25mL irinotecan hydrochloride trihydrate 500mg/25mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd

Pages

First page
Previous page
…
Page 54
Page 55
Page 56
Page 57
Current page 58
Page 59
Page 60
Page 61
Page 62
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.